RJK002 Intrathecal injection

DRUG2 trials

Sponsors

RJK Biopharma Ltd

Conditions

Amyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis Als

Early Phase 1

An IIT Clinical Study to Evaluate the Safety and Efficacy of a Single Intrathecal Injection of RJK002 in Patients With ALS

Active, not recruitingNCT06454682

RJK Biopharma LtdAmyotrophic Lateral Sclerosis

Start: 2023-09-11End: 2031-08-02Target: 9Updated: 2025-08-28

Phase 1

Evaluate the Safety and Efficacy of Intrathecal Injection of RJK002 in Patients With Amyotrophic Lateral Sclerosis

Active, not recruitingNCT06493279

RJK Biopharma LtdAmyotrophic Lateral Sclerosis Als

Start: 2024-09-24End: 2030-11-30Target: 9Updated: 2025-11-20